Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit
I'm PortAI, I can summarize articles.
Novo Nordisk A/S (NYSE:NVO) shares fell 3.40% to $56.91 after the company faced a lawsuit from Strive Specialties. The lawsuit alleges that Novo and Eli Lilly illegally blocked access to customized, lower-cost versions of their GLP-1 weight-loss drugs, claiming they used market dominance to prevent patients from obtaining compounded alternatives. Strive seeks monetary damages and a court order against the exclusivity agreements. Novo Nordisk stated that the claims are without merit and they will defend themselves vigorously in court.
Source: fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments